China Medicine Corp (CHME) Financier

China Medicine Corp. engages in the development, manufacture, and sale of western pharmaceuticals, traditional Chinese medicines, and other healthcare products. The company is headquartered in Guangzhou, Guangdong and currently employs 281 full-time employees. The company went IPO on 2005-06-23. The firm is engaged in the production and distribution of prescription and over the counter (OTC) drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The firm is developing a number of products for a range of indications, including oncology, high blood pressure and the removal of toxins from food and animal feeds. The firm's products include Shuangdan Capsules, Houerhuan Anti-inflammatory Capsules, Shugan Yipi Granules, Danggui Tiaojing Granules, Huangzao Granules, Pingfeng Shengmai Capsules, Danqi Tablets and Naodesheng Tablets. The firm also offers a range of dietary supplements, which include BeThin Tablets, Refrelizer Herbal Tea, LifeFull Herbal Tea and Relaxetox Herbal Tea. Shuangdan Capsules are indicated for the treatment of stagnation of the heart blood, obstruction of qi in the chest and cardiodynia.